Insider Selling: ALX Oncology Holdings Inc. (NASDAQ:ALXO) CAO Sells $10,026.50 in Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO) CAO Shelly Pinto sold 1,823 shares of the company’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $5.50, for a total value of $10,026.50. Following the completion of the transaction, the chief accounting officer now owns 92,113 shares in the company, valued at approximately $506,621.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shelly Pinto also recently made the following trade(s):

• On Monday, July 1st, Shelly Pinto sold 1,373 shares of ALX Oncology stock. The shares were sold at an average price of $5.82, for a total value of $7,990.86.

ALX Oncology Trading Up 13.9 %

Shares of ALXO opened at $7.70 on Friday. The business’s 50-day moving average price is $10.17 and its 200-day moving average price is $12.76. The company has a quick ratio of 5.21, a current ratio of 5.21 and a debt-to-equity ratio of 0.06. ALX Oncology Holdings Inc. has a twelve month low of $3.94 and a twelve month high of $17.83. The stock has a market cap of $401.17 million, a PE ratio of -2.07 and a beta of 1.06.

ALX Oncology (NASDAQ:ALXO) last posted its earnings results on Thursday, May 9th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.16. On average, equities analysts forecast that ALX Oncology Holdings Inc. will post -2.89 EPS for the current fiscal year.

Institutional Investors Weigh In On ALX Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in ALXO. CANADA LIFE ASSURANCE Co purchased a new position in ALX Oncology during the first quarter worth about $27,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of ALX Oncology in the fourth quarter worth approximately $28,000. EntryPoint Capital LLC purchased a new stake in ALX Oncology in the first quarter valued at approximately $32,000. China Universal Asset Management Co. Ltd. raised its stake in ALX Oncology by 445.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock valued at $86,000 after purchasing an additional 4,706 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new stake in ALX Oncology during the third quarter valued at approximately $168,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ALXO shares. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a report on Wednesday, May 29th. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of ALX Oncology in a research note on Monday, June 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.67.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.